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Summary A phase II trial with mitozolomide was carried out in patients with malignant melanoma, since in
preclinical studies this new imidazotetrazine had shown promising effects against human melanoma
xenografts. Twenty-one evaluable patients with advanced malignant melanoma were teated with 115mgm-2
of mitozolomide, given orally every 6 weeks. None of the patients had received prior chemotherapy. Two
partial responses (10 and 7+ months) were observed. The responding patients had lung metastases, and one
of them had, in addition, a huge (17 x 14cm) lymph node metastasis in the groin. Also, one patient had a
48% tumour volume reduction of lung metastases. The dose limiting side effect of the treatment was bone
marrow depression, with delayed leukopenia and thrombocytopenia. The median white blood cell counts and
platelet nadirs were 2.5 x 1091-1 (range 1.1-3.8) and 59 x 109 11 (range 14-95), respectively. Non-
haematological adverse reactions were limited to mild or moderate nausea. It is concluded that orally
administered mitozolomide is active against malignant melanoma and seems to have a response rate
comparable to those of the most active established drugs.
Malignant melanoma is a relatively frequent type of cancer
which in Norway has shown an increasing incidence during
the last decade (Magnus, 1981). In patients with recurrent
disease radiation treatment has limited activity, and the most
active chemotherapeutic drugs give response rates of
approximately 10-20% only. In our institution DTIC, the
most widely used agent, has induced remission in 14% of the
more than 100 patients treated. During the last 10-15 years
no new compound has proved to be useful in the treatment
of malignant melanoma. Encouraging reports of early results
with combination chemotherapy regimens are rarely con-
firmed in sizeable series. In view of these observations it is
increasingly recognized that new chemotherapy regimens
should be tested as first line treatment in disseminated
malignant melanoma.
Mitozolomide (NSC 353451) is a new imidazotetrazine
(Stevens et al., 1984; Gibson et al., 1984) that has been
found to have a broad spectrum of activity against murine
tumours (Hickman et al., 1985). The effect of mitozolomide
on human cancers was examined in preclinical in vitro and in
vivo studies, and marked antitumour activity was observed in
melanomas, lung carcinomas and in some sarcomas (Fodstad
et al., 1985). Nude mice carrying a xenografted human
melanoma were cured of their tumours after treatment with
mitozolomide.
In phase I trial (Newlands et al., 1985), the most
prominent side effects observed were thrombocytopenia and
leucopenia. A dose of mitozolomide of 115mgm-2 was
recommended for further clinical trials. Since mitozolomide
had shown promising effects against melanoma zenografts, a
phase II trial itl patients with malignant melanoma was
initiated, administering the recommended dose orally every
six weeks. The results obtained indicate that mitozolomide is
a promising new agent in the treatment of melanoma.
Materials and methods
The patient characteristics are given in Table I. All patients
had histologically confirmed progressive malignant
melanoma with non-irradiated evaluable or measurable
lesions not amenable to curative surgery. None of the
patients had previously received chemotherapy. Oral
informed consent was obtained.
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Table I Patient characteristics
Number of evaluable patients 21
Men/women 11/10
Median age in years (range) 55 (29-70)
Median WHO performance score (range) 0.5 (0-2)
Prior chemotherapy 0
Number of indicator lesions
a. Regional nodes and/or skin 9
b. Lung metastases 10
c. Liver metastases 7
a+b+c 2
a+c I
Median number of courses (range) 2.3 (1-4)
Eligibility criteria included performance status (WHO)
<3, life expectancy >3 months, age <75 years and no CNS
involvement, white blood cell counts (WBC) >4,000mm-3,
platelet counts (PLTC) > 100,000mm-3, serum bilirubin
level <2.0mgdl- 1 and serum creatinine level <1.5mgdl-1.
Initial work-up consisted of case history and physical
examinations, complete blood cell counts, routine chemistry
profile, chest X-rays and electro-cardiogram. Blood cell
counts were repeated weekly. Other tests were repeated as
indicated.
Mitozolomide was supplied by May & Baker Ltd.
(Dagenham, UK), as colour coded capsules of 50, 60 and
70mg. The drug was given orally at a dose of 115mgm-2,
repeated every 6th week. Dose adjustments were made
depending on the lowest value of WBC and PLTC on day 8,
15, 22 and 29 in the previous course, taking into account
possible treatment delay due to myelosuppression. The dose
was increased by 20% with WBC >4,000mm-3 and PLTC
>100,000 mm-3. The dose was reduced by 25% with WBC
between 1,000 and 1,999mm-3 or PLTC between 50,000 and
74,999mm-3, and with 50% for values below 1,000mm-3
and 50,000mm - , respectively. Drug administration was
postponed by 1 week if at scheduled retreatment full
haematological recovery (WBC >4,000mm -3 and PLTC
> 100,000mm-3) from prior course of therapy had not
taken place. If the treatment was delayed because of myelo-
suppression at scheduled retreatment, the drug dose was
reduced by 25%.
Treatment was continued until progression of the disease
if unmanageable toxicity did not develop. A minimum of 2
courses of therapy was found necessary for assessment of
treatment effects, unless clear progression of the disease was
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observed already after one course. The criteria for response
were: Complete response (CR) is defined as a disappearance
of all known disease, determined by two observations not
less than 4 weeks apart: partial response (PR) means a
decrease by at least 50% in the sum of the products of the
largest perpendicular diameters of all measurable lesions,
determined by two observations not less than 4 weeks apart;
no change is defined as a <50% decrease in total tumour or
25% increase in the size of one or more measurable or
evaluable lesions; progressive disease is defined as a >25%
increase in the size of at least one indicative lesion or the
appearance of a new lesion.
Results
Among 23 eligible patients, there were two early deaths (<6
weeks after first course), unrelated to mitozolomide therapy.
One of the other 21 patients received 1 course of treatment,
12 patients received 2 courses, 7 patients received 3 courses
and 1 patient received 4 courses of mitozolomide. Twelve
patients had dose reductions due to leukopenia or thrombo-
cytopenia grade 3-4. Three dose escalations were undertaken.
Altogether two definite partial responses were seen
(>90% tumour volume reduction) (Table II). In addition
one patient had an almost (48%) partial response. All
responding patients had lung metastases and one patient had
in addition a partial remission of a very large lymph node
metastasis in the groin. The duration of the remissions were
10 and 7+ months. Six patients with progression before
therapy had stable disease. The remaining 13 patients had
progressive disease, and 8 of these had died of their cancer
at the time of assessment of the results.
Bone marrow suppression was the main toxic side effect.
After the first course of treatment the median WBC and
platelet nadirs were 2.4 (1.1-3.6)x 1091-1 and 56 (14-
86) x 1091-1. For all courses, the nadir values were 2.5 (1.1-
3.8)x 1091-I and 59 (14-95)x1091-1. Haematologic values
according to cycle and weeks after treatment are shown in
Table III. The number of delayed cycles due to myelo-
suppression was 17 while 19 courses were reduced in dosage
and one escalated.
Five patients had nausea and vomiting of WHO grade 0,
eight patients of grade 1, and 8 patients of grade 2. Alopecia
was not seen in any of the patients. In general, the subjective
side effects of mitozolomide were mild to moderate.





evaluable patients CR PR NC PD
21 0 2a 6b 13
aDuration: 10 and 7+ months; bOne patient
with a 48% tumour volume reduction.
Discussion
The lack of chemotherapeutic agents effective against
malignant melanoma has during the last 10 years prompted
the testing of numerous new drugs in clinical phase II trials
in melanoma patients, unfortunately with very limited
success. Therefore, there seems to be a need for compounds
that have been more carefully selected before being entered
into clinical trials.
During the development and early testing of a series of
imidazotetrazines at the University of Aston, Birmingham,
one of these, mitozolomide, was found to be very active
against murine tumours (Stevens et al., 1984; Hickman et al.,
1985). Subsequent preclinical evaluation of this compound in
human tumour models in our institution indicated that
mitozolomide might be effective against malignant
melanoma (Fodstad et al., 1985), a finding that initiated the
clinical phase II trial reported here. The results obtained
show that mitozolomide has activity in advanced malignant
melanoma and suggest that its clinical potential should be
further examined.
Two definite (>90% tumour volume reduction) partial
responses to mitozolomide were seen in 21 evaluable
patients. In addition, one patient had 48% reduction in
tumour volume, i.e. a near partial remission. Five patients
had no change in their disease. This response rate indicates
that mitozolomide is approximately as active as DTIC and
CCNU, two of the most commonly used, but not very
effective, agents in malignant melanoma. Thus, in spite of
the positive effects seen with mitozolomide, the data do not
nourish hopes of significant improvement in the treatment of
melanoma. Nevertheless, mitozolomide may represent an
additional drug that might be valuable in combination with
other compounds. Indications exist that mitozolomide may
show cross-resistance with CCNU, and the data so far
obtained in melanoma xenografts in nude mice (Fodstad et
al., 1985) support this possibility. However, in xenografts of
other tumour types, such as lung carcinomas and sarcomas,
such cross reactivity has not been observed (Fodstad et al.,
Unpublished).
The pattern of side effects observed in the patients in the
present trial is very much in agreement with that seen in the
phase I trial. The myelosuppression shows a delayed
recovery, similar to that seen with CCNU. This myelo-
suppression, especially the thrombocytopenia, seems to
represent the dose limiting side effect of mitozolomide. Apart
from moderate nausea the drug was subjectively well
tolerated by the patients, and it did not cause alopecia. In
the phase I trial, doses of mitozolomide of up to 190mgm-2
did not cause serious toxicity to other normal tissues.
Since mitozolomide clearly is active against malignant
melanoma, and because of the apparent selective nature of
its bone marrow toxicity, a possible area of use of mitozolo-
mide might be in conjunction with autologuous bone
marrow transplantation. Thus, after aspiration of bone
marrow, the patients could be treated with very high,
otherwise intolerable, doses of mitozolomide before the bone
marrow is reinfused into the patient.
Mitozolomide was selected for clinical testing in malignant
Table III Haematologic values according to cycle and weeks after treatment. Median values (range). Upper values white
blood cells, lower values platelets
Cycle Ist week 2nd week 3rd week 4th week 5th week 6th week
1 6.2 (5.5-9.7) 6.2 (3.3-11.2) 5.0 (3.1-8.3) 4.6 (1.5-10.4) 3.2 (1.1-9.3) 3.3 (1.2-9.7)
310 (182-649) 188 (15-710) 92 (38-310) 80 (14-838) 156 (21-219) 381 (196-695)
2 5.3 (3.5-8.1) 5.9 (2.9-9.7) 4.7 (2.9-9.0) 5.6 (2.0-12.0) 5.0 (2.3-7.4) 3.6 (2.0-10.0)
403 (175-550) 210 (94-587) 129 (55-287) 156 (85-440) 186 (40-584) 246 (89-652)
3 5.6 (2.9-11.9) 5.6 (3.2-11.7) 5.3 (2.8-10.5) 5.0 (4.3-11.3) 4.5 (3.4-6.7) 5.1 (2.9-6.5)
259 (15-584) 254 (16-330) 127 (19-323) 169 (44-398) 158 (77-445) 173 (53-105)PHASE II TRIAL OF MITOZOLOMIDE IN MELANOMA 435
melanoma patients based on the promising effects seen in
human tumour models. During the last 7-8 years, several
new compounds have been examined in phase II trials in this
hospital without similar preclinical indications of activity in
human melanoma. No clinical response was observed with
any of these drugs, in contrast to the situation with mito-
zolomide. It may be recommended, therefore, that before a
new drug is entered into clinical testing in malignant
melanoma, the effect of the compound should be assessed in
human tumour models.
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